Post

Coronary and Carotid Embolic Protection Devices - Performance Testing and Labeling Requirements

This guidance addresses coronary and carotid embolic protection devices designed to capture and remove embolic material during interventional treatment of carotid arteries or saphenous vein bypass grafts. It covers devices used along with other interventional devices for: - Treatment of diseased saphenous vein grafts in patients with stable ischemic coronary artery disease - Treatment of diseased carotid arteries that could potentially contribute to strokes or neurological adverse events

  1. Develop comprehensive bench testing plan covering all required performance characteristics
  2. Plan and execute animal studies following GLP requirements with both acute and chronic timepoints
  3. Design clinical study with appropriate endpoints and follow-up requirements
  4. Implement biocompatibility testing program per ISO 10993-1
  5. Validate sterilization process and establish shelf life
  6. Develop comprehensive labeling including all required warnings, contraindications and instructions
  7. Consider early engagement with FDA through Pre-IDE process, especially for novel technologies
  8. Establish quality system controls for design, manufacturing and testing
  9. Prepare documentation demonstrating compliance with all applicable standards
  10. Develop training program for healthcare practitioners

Key Considerations

Clinical testing

  • Primary endpoint of major adverse cardiac events (MACE) at 30 days for coronary devices
  • Primary endpoint of major adverse cardiac and cerebrovascular events at 30 days for carotid devices
  • Independent Clinical Events Committee and Data Monitoring Committee recommended
  • Core laboratory recommended for data analysis
  • Office visits required for follow-up (no telephone follow-up)

Non-clinical testing

  • Animal studies required with acute (24-72h) and chronic (1 month) timepoints
  • Animal model should mimic target anatomy
  • Study protocol should simulate clinical procedure
  • Assess vascular injury, inflammation, and neointimal response
  • Evaluate hemolysis potential
  • Assess device removal with full embolic load

Software

  • Software validation required if device contains software
  • Follow FDA guidance for software in medical devices

Labelling

  • Clear instructions for use by healthcare practitioners
  • Description of device failure modes and mitigations
  • List of contraindications
  • Specific warnings and precautions
  • Summary of clinical study results
  • Training program recommendations

Biocompatibility

  • Testing per ISO 10993-1 for blood-contacting devices
  • Cytotoxicity testing
  • Sensitization testing
  • Hemocompatibility testing
  • Material-mediated and endotoxin-mediated pyrogenicity testing

Safety

  • Sterilization validation to SAL 10-6
  • Shelf life testing for package integrity and device functionality
  • Pyrogenicity testing required

Other considerations

  • ISO 10993-1: Biological Evaluation of Medical Devices - Evaluation and Testing
  • ISO 10993-12: Biological Evaluation of Medical Devices - Sample Preparation and Reference Materials
  • ASTM F2065: Standard Practice for Testing for Alternative Pathway Complement Activation in Serum by Solid Materials
  • ASTM F1984: Standard Practice for Testing for Whole Complement Activation in Serum by Solid Materials
  • EN 60601-1: General Requirements for Safety
  • EN 60601-1-1: Safety Requirements for Medical Electrical Systems
  • EN 60601-1-2: Electromagnetic Compatibility – Requirements and Tests

Original guidance

  • Coronary and Carotid Embolic Protection Devices - Performance Testing and Labeling Requirements
  • HTML / PDF
  • Issue date: 2008-02-15
  • Last changed date: 2020-03-20
  • Status: FINAL
  • Official FDA topics: Medical Devices, 510(k), Premarket
  • ReguVirta summary file ID: b7d01294c312f360f96fbdff7ca8a0bd
This post is licensed under CC BY 4.0 by the author.